Health
U.S. faces highest flu hospitalization rate in a decade with young kids and seniors most at risk
The U.S. is facing the highest flu hospitalization rates in more than a decade with children and the elderly most at risk, according to the Centers for Disease Control and Prevention. Flu and respiratory syncytial virus had receded during the Covid-19 pandemic due to mitigation measures such as masks and social distancing. But as people […]
Read More
U.S. faces pandemic crossroads with Covid deaths still too high and new omicron variants emerging, Fauci says
Dr. Anthony Fauci, White House Chief Medical Advisor and Director of the NIAID, responds to questions from Sen. Rand Paul (R-KY) at a Senate Health, Education, Labor, and Pensions Committee hearing on Capitol Hill on January 11, 2022 in Washington, D.C. Greg Nash | Pool | Getty Images White House chief medical advisor Dr. Anthony […]
Read More
4 of our stocks are in the news. Here’s the Club’s take on each development
Four of our Club holdings — Costco Wholesale (COST), Amazon (AMZN), Humana (HUM) and Bausch Health (BHC) — were in the news Thursday. Here’s how we feel about the developments. Costco The news: Costco reported sales for the retail month of October after the closing bell Wednesday evening. In the four-week period, net sales increased 7.7% […]
Read More
New obesity drugs win support of doctors and insurers, which could lift these pharma names even higher
Drugs that treat obesity and overweight are improving their efficacy. They are also increasingly being prescribed by doctors and covered by insurers – a win for patients and for investors. “While supply is still a top concern for Wegovy, we’ve been impressed with commercial formulary access for obesity,” Geoff Meacham, an analyst at Bank of […]
Read More
2 takeaways from our daily meeting: Selling in an overbought market, updates on 3 holdings
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Thursday’s key moments. It’s not too late to sell Quick mentions: QCOM, COST, HUM 1. It’s not too late to sell Stocks fell on Thursday, continuing Wednesday’s losses after the Federal Reserve reaffirmed […]
Read More
Magic mushroom compound psilocybin can help treat depression, study finds
The naturally occurring psychedelic compound psilocybin can significantly reduce symptoms of depression, according to data from the largest trial of its type ever conducted. David Buzzard – media-centre.ca / Getty Images LONDON — The naturally occurring psychedelic compound psilocybin can significantly reduce symptoms of depression, according to data from the largest trial of its type […]
Read More
Moderna shares plummet after Covid vaccine maker lowers 2022 sales outlook
A vial of the Moderna coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, September 8, 2022. Hannah Beier | Reuters Moderna on Thursday lowered its 2022 sales guidance for its Covid-19 vaccine after missing Wall Street expectations for the third quarter. The Boston […]
Read More
We’re impressed with health insurer Humana’s solid quarter and rosy outlook for next year
Club holding Humana (HUM) reported a mixed-but-solid third quarter before the opening bell Wednesday. Early optimism about 2023 also supported our bullish view on the health insurer’s stock. Revenue increased 9% year-over-year to $22.75 billion, slightly below estimates of $22.76 billion, and adjusted earnings-per-share increased 42% to $6.88, exceeding estimates of $6.28 per share. Aiding […]
Read More
2 takeaways from our daily meeting: Stocks await Fed decision, Club earnings recap
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. Fed decision ahead Quick takes on Club earnings 1. Fed decision ahead Stocks edged down Wednesday ahead of the Federal Reserve’s decision on interest rate increases, set for this afternoon. […]
Read More
Eli Lilly’s guidance cut is about the strong dollar, not weakening fundamentals, CEO says
Eli Lilly (LLY) CEO David Ricks on Tuesday expressed optimism around the drugmaker’s innovation pipeline Tuesday, a stance we share despite the Club holding’s cluttered quarterly report issued earlier in the day . “The underlying fundamentals of the business are really strong,” Ricks said in a CNBC interview with Jim Cramer. “Seventy percent of our […]
Read More